Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/jcm11123518
Keywords
primary open-angle glaucoma; bimatoprost; benzalkonium chloride; break-up time (BUT) test; ocular surface disease index (OSDI); intraocular pressure (IOP)
Categories
Ask authors/readers for more resources
This study evaluated the therapeutic switch from Bimatoprost formulations with or without benzalkonium chloride (BAK) to a preservative-free formulation and its impact on eye surface conditions and intraocular pressure (IOP) in glaucoma patients. The results showed that Bimatoprost 0.1 mg/mL preservative-free had better tolerability and improved eye surface conditions compared to other formulations, but had slightly inferior IOP control.
This study aimed to evaluate whether the therapeutic switch from a formulation of Bimatoprost 0.1 mg/mL with benzalkonium chloride (BAK) or Bimatoprost 0.3 mg/mL preservative-free to a formulation of Bimatoprost 0.1 mg/mL preservative-free could improve eye surface conditions in patients with glaucoma; intraocular pressure (IOP) was also evaluated. All patients meeting the inclusion criteria were eligible for the therapeutic switch to Bimatoprost 0.1 mg/mL preservative-free. At each check visit, enrolled patients underwent a break-up time (BUT) test, an ocular surface disease index (OSDI) test, and a three-point tonometric curve. A total of 40 patients were enrolled (23 were in therapy with Bimatoprost 0.1 mg/mL with BAK and 17 with Bimatoprost 0.3 mg/mL preservative-free). Significant differences of OSDI and BUT between Bimatoprost 0.1 mg/mL with BAK at baseline vs. Bimatoprost 0.1 mg/mL preservative-free at 14 and 28 days (p < 0.0001 and p = 0.0003, respectively) were recorded. Similarly, significant differences of OSDI and BUT between Bimatoprost 0.3 mg/mL preservative-free at baseline vs. Bimatoprost 0.1 mg/mL preservative-free at 14 and 28 days (p < 0.0001 for both) were found. Bimatoprost 0.1 mg/mL preservative-free has a better tolerability profile associated with non-therapeutical inferiority in the control of IOP compared to the other Bimatoprost formulations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available